Type III-B CRISPR-Cas cascade of proteolytic cleavages
Science · 02.02.2024 · 383 (6682) · 512-519
DOI: 10.1126/science.adk0378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 02.02.2024. Verfasst von Jurre A Steens und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Microbiology, Wageningen University and Research, Wageningen, Netherlands. Hauptthemen laut MEDLINE: Bacterial Proteins, Caspases, CRISPR-Associated Proteins, CRISPR-Cas Systems. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
The generation of cyclic oligoadenylates and subsequent allosteric activation of proteins that carry sensory domains is a distinctive feature of type III CRISPR-Cas systems. In this work, we characterize a set of associated genes of a type III-B system from Haliangium ochraceum that contains two caspase-like proteases, SAVED-CHAT and PCaspase (prokaryotic caspase), co-opted from a cyclic oligonucleotide–based antiphage signaling system (CBASS). Cyclic tri–adenosine monophosphate (AMP)–induced oligomerization of SAVED-CHAT activates proteolytic activity of the CHAT domains, which specifically cleave and activate PCaspase. Subsequently, activated PCaspase cleaves a multitude of proteins, which results in a strong interference phenotype in vivo in Escherichia coli. Taken together, our findings reveal how a CRISPR-Cas–based detection of a target RNA triggers a cascade of caspase-associated proteolytic activities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Microbiology, Wageningen University and Research, Wageningen, Netherlands.
- Scope Biosciences B.V., Wageningen, Netherlands.
- Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
- Biomolecular Mass Spectrometry and Proteomics, University of Utrecht, Utrecht, Netherlands.
ORCID-Profile: Jurre A Steens, Jack P K Bravo, Carl Raymund P Salazar, Afonso M Amieiro, Stephan Köstlbacher, Stijn H P Prinsen, Constantinos Patinios, Andreas Bardis, Richard A Scheltema, Thijs J G Ettema, John van der Oost, David W Taylor, Raymond H J Staals
Förderung
- NIGMS NIH HHS
Zitieren
APA
Steens, J. A., Bravo, J. P. K., Salazar, C. R. P., Yildiz, C., Amieiro, A. M., Köstlbacher, S., Prinsen, S. H. P., Andres, A. S., Patinios, C., Bardis, A., Barendregt, A., Scheltema, R. A., Ettema, T. J. G., van der Oost, J., Taylor, D. W., & Staals, R. H. J. (2024). Type III-B CRISPR-Cas cascade of proteolytic cleavages. Science, 383(6682), 512-519. https://doi.org/10.1126/science.adk0378
Vancouver
Steens JA, Bravo JPK, Salazar CRP, Yildiz C, Amieiro AM, Köstlbacher S, et al. Type III-B CRISPR-Cas cascade of proteolytic cleavages. Science. 2024;383(6682):512-519. doi:10.1126/science.adk0378
BibTeX
@article{Steens2024,
author = {Steens, Jurre A and Bravo, Jack P K and Salazar, Carl Raymund P and Yildiz, Caglar and Amieiro, Afonso M and Köstlbacher, Stephan and Prinsen, Stijn H P and Andres, Ane S and Patinios, Constantinos and Bardis, Andreas and Barendregt, Arjan and Scheltema, Richard A and Ettema, Thijs J G and van der Oost, John and Taylor, David W and Staals, Raymond H J},
title = {Type III-B CRISPR-Cas cascade of proteolytic cleavages},
journal = {Science},
year = {2024},
volume = {383},
number = {6682},
pages = {512--519},
doi = {10.1126/science.adk0378}
}
EUVIMED